Lazar Mandinov
Corporate Officer/Principal bei The European Society of Cardiology
Aktive Positionen von Lazar Mandinov
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| The European Society of Cardiology | Corporate Officer/Principal | - | - |
Karriereverlauf von Lazar Mandinov
Ehemalige bekannte Positionen von Lazar Mandinov
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Maine Medical Center Research | Corporate Officer/Principal | - | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Lazar Mandinov
| Medical University Sofia | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Frankreich | 2 |
| Bulgarien | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BOSTON SCIENTIFIC CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
| The European Society of Cardiology | |
| Maine Medical Center Research |
- Börse
- Insiders
- Lazar Mandinov
- Erfahrung
